anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Reproduction studies have been performed in rats and mice at doses up to six times the usual daily human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to ciprofloxacin. In rabbits, as with most antimicrobial agents, ciprofloxacin (30 and 100 mg/kg orally) produced gastrointestinal disturbances resulting in maternal weight loss and an increased incidence of abortion. No teratogenicity was observed at either dose.

After intravenous administration, at doses up to 20 mg/kg, no maternal toxicity was produced and no embryotoxicity or teratogenicity was observed. There are no adequate and well controlled studies in pregnant women. Ciprofloxacin Ophthalmic Solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Non-cystic fibrosis bronchiectasis is a respiratory disease characterized by persistent airway inflammation and dilation of bronchial wall driven by various causes. Patients with bronchiectasis suffer from excessive sputum production, recurrent exacerbations, and progressive airway destruction. It was reported that 30%-40% patients were infected with Pseudomonas aeruginosa. Major therapy for bronchiectasis is focused on breaking the "vicious cycle" of mucus stasis, infection, inflammation, and airway destruction. Currently a number of clinical trials have showed that macrolide effectively used in the treatment of non-CF bronchiectasis. Evidence has indicated that 14- and 15-membered ring macrolides possess immunomodulation and anti-inflammatory functions beyond their antimicrobial properties. However, the underlying mechanisms that account for the anti-inflammatory actions of macrolides have not yet to be elucidated, and the activities do not appear to be controlled by a single mechanism.Interleukin-18 (IL-18), along with interleukin-1b (IL-1b), is produced by inflammasomes when activated by a number of pathogen, environmental or host-derived danger signals. Inflammasomes are innate immune regulatory protein complexes which seem to play a key role in the host immune response of patients with Bronchiectasis. The aim of this study was to determine IL-18 levels in serum of patients with Bronchiectasis and to investigate whether macrolide could attenuate its levels.
The inventors have identified a novel cell-penetrating sequence, termed hAP10, from the C-terminus of the human protein Acinus. hAP10 was able to efficiently enter various normal and cancerous cells, likely through an endocytosis pathway, and to deliver an EGFP cargo to the cell interior. Cell penetration of a peptide, hAP10DR, derived from hAP10 by mutation of an aspartic acid residue to an arginine was dramatically increased. Interestingly, a peptide containing a portion of the heptad leucine repeat region domain of the survival protein AAC-11 (residues 377-399) fused to either hAP10 or hAP10DR was able to induce tumor cells death in vitro and to inhibit tumor growth in vivo in a sub-cutaneous xenograft mouse model for the Sézary syndrome. Combined, the results indicate that hAP10 and hAP10DR may represent promising vehicles for in vitro or in vivo delivery of bioactive cargos, with potential use in clinical settings. Thus the present invention relates to cell penetrating peptides and uses thereof for intracellularly delivery of molecules.
LEPAD patients achieving a 12-week program of neuromuscular electrical stimulation. Group of arteriopathic patients who will perform electrostimulation sessions at home and independently. These patients will also receive a study participation guide that will include an information leaflet outlining tips for active living and walking.
The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises device at home. Patient received 3 sessions of dry needling a week for four weeks.
HF patients with functional iron deficiency assigned to receive one-time dose of Placebo (saline injection). Participants will undergo serial assessment before and 4 weeks after study drug administration.
PURPOSE:The titled composition having reduced damage due to the polymerization shrinkage, containing a polymerizable monomer having a polyether group and/or hydroxyl group and polymerizable vinyl group and a polymerizable monomer having a carboxyl group and polymerizable vinyl group. CONSTITUTION:A composition for a dental resin containing a monomer having a polyether group and/or hydroxyl group and a polymerizable vinyl group, e.g. bisphenol A type epoxy acrylate, and a monomer having a carboxyl group and polymerizable vinyl group, e.g. acrylic acid, at (20-97.5):(2.5-80) weight ratio. The composition is suitable to a facing hard resin, for a plate or adhesive resin cement, etc. The easy prosthodontic operation in applying and padding a kneaded material of a liquid component consisting of the composition and powder component on a cast crown, etc. and the reduced polymerization shrinkage provide the reduction in damage.
Risk Summary

Lactation studies have not been conducted with bupivacaine. Bupivacaine has been reported to be excreted in human milk suggesting that the nursing infant could be theoretically exposed to a dose of the drug. MARCAINE / MARCAINE WITH EPINEPHRINE should be administered to lactating women only if clearly indicated. Studies assessing the effects of MARCAINE / MARCAINE WITH EPINEPHRINE in breastfed children have not been performed. Studies to assess the effect of MARCAINE / MARCAINE WITH EPINEPHRINE on milk production or excretion have not been performed. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for bupivacaine and any potential adverse effects on the breastfed child from bupivacaine or from the underlying maternal condition.
Ampicillin and sulbactam for injection is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below.

Skin and Skin Structure Infections caused by beta-lactamase producing strains of Staphylococcus aureus, Escherichia coli,*Klebsiella  spp.* (including K. pneumoniae*), Proteus mirabilis,*Bacteroides fragilis,*Enterobacter spp.,* and Acinetobacter calcoaceticus.*

NOTE: For information on use in pediatric patients see PRECAUTIONS-Pediatric Use and CLINICAL STUDIES sections.

Intra-Abdominal Infections caused by beta-lactamase producing strains of Escherichia coli, Klebsiella spp. (including K. pneumoniae*), Bacteroides spp. (including B. fragilis), and Enterobacter spp. *

Gynecological Infections caused by beta-lactamase producing strains of Escherichia coli,* and Bacteroides spp.* (including B. fragilis*).

* Efficacy for this organism in this organ system was studied in fewer than 10 infections.

While ampicillin and sulbactam for injection is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with ampicillin and sulbactam for injection due to its ampicillin content. Therefore, mixed infections caused by ampicillin-susceptible organisms and beta-lactamase producing organisms susceptible to ampicillin and sulbactam for injection should not require the addition of another antibacterial.

Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify the organisms causing infection and to determine their susceptibility to ampicillin and sulbactam for injection.

Therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above in the indicated organ systems. Once the results are known, therapy should be adjusted if appropriate.

To reduce the development of drug-resistant bacteria and maintain effectiveness of ampicillin and sulbactam for injection and other antibacterial drugs, ampicillin and sulbactam for injection should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
A comparative study was performed to investigate the physicochemical properties and protective effects of hydrochloric acid-resistant dextrin (H-RD), citric acid-resistant dextrin (C-RD) and tartaric acid-resistant dextrin (T-RD) on the metabolic disorders and intestinal microbiota for type 2 diabetes mellitus (T2DM) mice. T-RD had the minimum molecular weight, with the highest short chain (DP 6-12) proportion and resistant starch content. After 4-week intervention with the three resistant dextrins, the body weight and fasting blood glucose of T2DM mice were improved significantly, accompanied by the reduction of serum indexes (TG, TC, LDL-C, ALT, AST, CRE, BUN, FINS, and GSP), but the serum HDL-C and liver glycogen levels increased. Among the three RDs intervention groups, T-RD showed the most significant improvement, followed by C-RD and finally H-RD. The 16 s rDNA results indicated that oral administration of resistant dextrins favored the proliferation of specific gut microbiota, including Faecalibaculum, Parabacteroides and Dubosiella, and reduced the ratio of Firmicutes/Bacteroidota, which is beneficial for reducing insulin resistance. Herein, the findings supported that the resistant dextrins exhibited a remission effect on T2DM, providing a basis for the development of functional food adjuvants for T2DM treatment.
PURPOSE:To obtain the subject new stable compound, excellent in scavenging effects on active oxygen radicals in the living body, useful as a cytotoxicity protecting agent and having low toxicity. CONSTITUTION:This compound is expressed by the formula (R<1> is a 5-22C saturated or unsaturated fatty acid acyl residue; R<2> is a 1-5C alkyl), e.g. 3-tert- butyl-4-hydroxyphenyl decanoate. The compound expressed by the formula is obtained by reacting hydroquinones with an active derivative of a fatty acid (e.g. a fatty acid chloride) in the presence of a basic catalyst (e.g. N,N- dimethylaminopyridine). The compound is effective against diseases requiring the protection of cytotoxicity due to active oxygen radicals such as diseases in circulatory organs, e.g. ischemic cardiopathy, ischemic cerebropathy or arteriosclerosis, diseases in digestive organs, e.g. an alimentary canal, the liver or the pancreas, dermatopathy, cancer or pulmonopathy and inflammations and further useful as a raw material for foods, medicines, cosmetics, etc.
The present invention relates to a system and to a corresponding method for an automated triggering and management of alarms, in particular in a home environment ( 1 ), comprising at least one sensor ( 21, 22,  . . . ) for collecting data and for transmitting the collected data over at least one first data connection ( 31, 32,  . . . ) to a central unit ( 4 ), in which the central unit ( 4 ) comprises at least one receiving module ( 41 ) for receiving transmitted data and for forwarding the received data to an analyzing module ( 42 ), the analyzing module ( 42 ) being capable of comparing the received data with data stored in the analyzing module ( 42 ) and, forwarding the received data to a triggering module ( 43 ) for triggering at least one predetermined alarm as a function of the data received from the analyzing module ( 42 ) if the received data matches data stored in the analyzing module ( 42 ), or forwarding the received data to central processing equipment ( 6 ) over a second data connection ( 51 ) if the received data does not match data stored in the analyzing module ( 42 ).
A system includes a processor circuit in communication with an intraluminal imaging device. The processor circuit is configured to receive an intraluminal image obtained by the intraluminal imaging device while the intraluminal imaging device is positioned within a body lumen of a patient. The processor circuit also receive a user input selecting one location within the intraluminal image and another user input selecting another location within the intraluminal image. These two locations within the intraluminal image define boundaries of a sector of the intraluminal image associated with a tissue type. The processor circuit determines an angle of the sector defined by the two locations. The intraluminal image and a visual representation of the angle are displayed on a screen display.
A sterile pyrogen free Re¹⁸⁶ or Re¹⁸⁸ radiopharmaceutical is prepared by reducing radio­active perrhenate in the presence of a bone seeking ligand to form a solution including complexed Re-ligand compound together with impurities such as uncomplexed perrhenate, ReO₂ and free ligand. The radiopharmaceutical is obtained by a low pressure purification method. The solution is added to a separation column (12), preferably an ion exchange column, and a first portion is eluted and discarded. The radiopharmaceutical is collected in a second eluted portion defined as having 25-85% of the activity of the Re on the column, less than 10% unligated perrhenate and less than 1% ReO₂. This can be used as is to image and treat metastatic bone lesions. A simple kit is also disclosed.
FIELD: medicine, immunology, phytotherapy. SUBSTANCE: invention relates to medicinal agents with an immunostimulating effect from vegetable raw and to a method of their preparing, namely, to a medicinal agent with an immunostimulating effect. The preparation comprises polysaccharides from Pleurotes ostreatus with molecular mass 10-420 kDa as an active component. Method of the preparation preparing involves preliminary drying fungus parts, milling, removal of lipids by extraction with an alcohol-containing solution, isolation of an active component from precipitate by extraction with boiling water, concentrating, precipitation of polysaccharides by treatment with an alcohol-containing solution and dialysis. EFFECT: preparing novel preparation showing immunostimulating effect. 6 cl, 6 tbl, 3 ex
Participants in the placebo group will be asked to take a placebo pill 1.5 hours before the experimental session. One hour later (30 minutes before testing begins), participants will be asked to chew a placebo gum.
Art therapy workshops : groups of 6 to 12 patients supervised over a session of 1.5 to 2 hours, in the presence of an artist and the nursing staff (psychologist, nurse, doctor). There are 6 sessions per group, with an average of one week between sessions.
Part 1: This is an open-label, randomized, two-period, two-sequence, crossover study in healthy subjects. The study will consist of a screening phase, a baseline phase, two treatment periods, and a follow-up phone call. Each period will be ten days in duration including 7 days of dosing and sample collection for up to 72 hours post Day 7 morning dose. There will be a washout between period 1 and period 2.

Part 2: This is an open-label, randomized, four-period, four-sequence crossover study to evaluate the PK and exposure of apremilast following single dose administration of different formulations of apremilast. Part 2 will consist of a screening phase, baseline, four treatment periods, and a follow-up phone call. Each period will be four days in duration for dosing (Day 1) and sample collection for up to 72 hours post Day 1.
In addition to standard of care, participants will be asked to participate in rehabilitation sessions administered at home via live videoconferencing for approximately 60 minutes a session, three times a week. A total of 36 sessions will be planned to be completed by week 13 post-discharge. Exacerbations and health status will be ascertained every 4-weeks for 13 weeks.
Introduced here are approaches for capturing and recording medical event details during cardiopulmonary resuscitation (CPR) events and other emergency medical events. A recording begins when an operator inputs a request to initiate recording. The operator may use a recording system with a combination of input devices to record medical actions. The recording system acknowledges the operator's actions by various means which may include icons displayed for the operator. The operator's interactions with the icons indicate corresponding actions observed by the operator, which are recorded as a log of the actions in temporal order that serves as a non-transient record of the medical event. An analysis of the recorded details of the medical event, by comparing the actions to prescribed actions in one or more professional standards, can provide an assessment of the actions taken.
End stage renal disease (ESRD) patients requires hemodialysis to maintain bloodstream functions. Before the hemodialysis, the patients requires a long-term vascular access, which best choice is Arteriovenous fistulas (AVF). However, 1/3 of patients were failure in AVF maturation, and it is still unknown. Our preliminary data have shown that pre-exisiting fibrosis in vein of AVF failure. Here, we will investigate whether pre-existing fibrosis of vein is asssociated with circulating fibrocytes in AVF failure, and further to address molecular mechanism of fibrocytes differentiation. We will divide into three parts to carry out. Firstly, evidence the pre-existing fibrosis in vein of AVF failure patients. Secondary, investigation of expression, the role, and the mechanism by which the identified O-GlcNAac proteins promote, maturation of AV fistula. Finally, address and compare the proteomics differentiation between failure and maturation of AVF patients. We hope that through this project, we can obtain signifiture molecules for precision detection and solve the current clinical unmet need.
HFOV-sigh setting both SLE6000 and Drager Babylog VN500: setting (Hz, MAP, delta pressure) same as HFOV, set sigh RR 3 breath/min, Sigh Ti = 1 sec, Sigh PIP = (MAP+5, maximum 30) cm H2O, Slope sigh 0.5. No change in Hz, MAP, delta pressure, and increased FiO2 less than 0.1 occurred between intervention.
Accurate measurement of the pulmonary vein dimension (PVD) is important for determining stenosis and efficacy following pulmonary vein isolation (PVI). Little is known about the quantitative evaluation of the impact of the cardiac cycle on pulmonary vein (PV) morphology before and after PVI. This study aims to investigate variations in the ostial size of the PV during the cardiac cycle before and after PVI and the effect of the cardiac cycle on PV stenosis and reduction rate using cardiac computed tomography (CT). Sixty-eight patients with atrial fibrillation who underwent cardiac CT before and after PVI at our institution between 23 January 2021 and 5 February 2022 were retrospectively analyzed. The maximum and minimum PVD were measured at each segment before and after the PV. Each PV was evaluated according to the PVD reduction rate (ΔPVD), calculated as follows: (1 - post-PVD/pre-PVD) × 100 (%). The average dimension of all PVs at the end-diastolic frame was significantly reduced compared to that at the end-systolic frame before PVI. The average dimensions of the right superior and right inferior PV at the end-diastolic frame were significantly reduced compared with those at the end-systolic frame following PVI. The average reduction rate of dimension-classified stenosis of PVs, except for the left inferior PV at the end-diastolic frame, was significantly reduced compared with that at the end-systolic frame. The cardiac cycle affects PVD assessment, including PV stenosis, after PVI. PVD measurement is recommended to be unified to the end-systolic frame of the cardiac cycle to avoid underestimating PV stenosis before and after PVI, ensuring appropriate management and follow-up.
The present invention relates to a scuticociliates vaccine using frozen and deactivated scuticociliates M. avidus as an antigen of the vaccine and containing any one of peptidoglycan, lipoteichoic acid and β-glucan added thereto as an immune supporter. After carrying out a test introducing a scuticociliates vaccine composition to a test fish and making the test fish get infected with scuticociliates at the time of four weeks and eight weeks, a vaccine mixed with peptidoglycan as an immune supporter shows a significant difference as demonstrated by a high relative survival ratio of 55% or more in a test fish group infected with peptidoglycan at the time of four weeks as compared to the control group. In addition, in a vaccine group to which lipoteichoic acid is added, a low-concentration group shows an RPS of 40% at the time of four weeks of vaccine administration. In a test group to which β-glucan is added, 100 μg addition thereof results in an RIPS of 35% at the time of four weeks of vaccine administration and of 37% at the time of eight weeks of vaccine administration. In addition, in a 10 μg-added test group, an RPS of 32% is obtained at the time of eight weeks of vaccine administration. Thus, such immune supporters enhance immunity and thus are effective for controlling scuticociliates.
Dietary supplement with bilberry shakes 2 times daily for 3 months (containing in total 40g of dried bilberry powder equalling 480 g of fresh berries per day). Product development in collaboration with Glucanova AB.
FIELD: medicinal technique. SUBSTANCE: invention relates to a medicinal composition. Composition is placed into the first syringe chamber and comprises protein in the amount less 1.4 mg, amino acid and stabilizing agent. Mass ratio of protein to amino acid and stabilizing agent is less 1.5. Mass ratio of dry component to briquette volume in the first chamber exceeds 12 mg/ml. The second chamber containing an aqueous solution for diluting where volume to be injected is less 0.5 ml. Composition is useful for storage at room temperature for definite time. EFFECT: improved and valuable properties of composition. 8 cl, 4 tbl